Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth in 2025?
The market size for therapeutics and diagnostics relating to exocrine pancreatic insufficiency (EPI) has seen substantial growth recently. It’s anticipated that the market will increase from $5.69 billion in 2024 to $6.17 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.4%. This previous period of growth can be associated with a spike in pre-existing conditions, progression in diagnostic technologies, advancements in pharmaceuticals, and an increase in global healthcare accessibility.
What Is the Forecast for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size Through 2029?
Anticipated to experience robust expansion in the coming years, the market for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) is projected to reach a valuation of $8.32 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.8%. Factors attributing to the predicted growth during the forecast period include advancements in telemedicine and remote tracking, data analysis and artificial intelligence, patient instruction and support, along with regulatory amendments and reimbursement policies. Noteworthy trends during this forecast period encompass personalized treatment strategies, the invention of innovative therapies, minimally invasive diagnostic tools, and collaborative care paradigms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What are the Key Market Players in Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market and How They’re Evolving?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
What Are the Primary Growth Drivers in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to be driven by the escalating cases of diabetes. Diabetes is a chronic metabolic disorder typified by enduring hyperglycemia due to insufficient insulin production or ineffective utilization of produced insulin. Therapeutic interventions for EPI, such as pancreatic enzyme replacement therapy (PERT), have shown to be beneficial in boosting nutrient absorption and enhancing glycemic control in diabetic patients. For instance, The National Health Service (NHS England) reported that in June 2024, the prevalence of individuals identified with pre-diabetes in England rose by 18% from 3,065,825 in 2022 to 3,615,330 in 2023. In individuals below 40 years, the count increased by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising diabetic population is anticipated to bolster the growth of the EPI therapeutics and diagnostics market. The EPI therapeutics and diagnostics market is set for growth, driven by an upsurge in gastrointestinal diseases. These diseases impact the gastrointestinal tract that includes digestion-related organs. EPI therapeutics and diagnostics are vital in the management of these diseases, as they help in replenishing the deficient enzymes and facilitate proper digestion. For example, in June 2023, Crohn’s and Colitis Canada noted that over 322,600 Canadians, representing about 0.82% of the nation’s population, were living with inflammatory bowel diseases (IBD) in 2023. As IBD prevalence continues, the estimate is that by 2035, nearly 470,000 Canadians or approximately 1.1% of the population (1 in every 91 people) will be affected. Consequently, the spike in gastrointestinal diseases is expected to fuel the market growth for EPI therapeutics and diagnostics.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
What Are the Leading Segments in the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
What Are the Key Market Trends in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry?
Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are strategically partnering to enhance technological integration and broaden market penetration. This sort of strategic collaboration typically involves multiple organizations combining their resources, knowledge, and initiatives for shared objectives. For instance, Codexis, Inc., a protein engineering enterprise based in the United States, and Nestlé Health Science, a company dedicated to the science of nutrition from Switzerland, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI), in February 2023. These Phase 1 trial results open the door for more research that could dramatically improve therapy avenues for patients with EPI.
Access The Full Report Here:
What Is the Regional Outlook for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
This Report Delivers Insight On:
1. How big is the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and how is it changing globally?
2. Who are the major companies in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and how are they performing?
3. What are the key opportunities and risks in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market right now?
4. Which products or customer segments are growing the most in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
5. What factors are helping or slowing down the growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
